China Biologic Products 10-Q 5 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 05, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'China Biologic Products, Inc.	'
Entity Central Index Key	'0001369868	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Trading Symbol	'CBPO	'
Entity Common Stock, Shares Outstanding	'	24,656,612

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$74,578,792	$144,138,487
Time deposit	0	6,608,612
Restricted deposits	63,521,250	0
Accounts receivable, net of allowance for doubtful accounts	24,667,887	17,270,132
Inventories	96,669,939	88,634,855
Prepayments and other current assets	16,009,141	7,641,061
Total Current Assets	275,447,009	264,293,147
Property, plant and equipment, net	78,720,377	73,149,072
Land use rights, net	10,111,002	8,213,145
Deposits related to land use rights	12,760,943	13,667,130
Restricted cash and deposits, excluding current portion	40,131,390	30,523,674
Equity method investment	13,042,867	11,349,807
Other non-current assets	3,603,998	2,585,232
Total Assets	433,817,586	403,781,207
Current Liabilities	'	'
Short-term bank loans, including current portion of long-term bank loans	75,700,000	9,822,000
Accounts payable	4,809,253	4,445,732
Due to related parties	3,952,901	7,206,970
Other payables and accrued expenses	37,266,208	34,852,740
Advance from customers	1,525,251	2,908,853
Income tax payable	5,236,452	4,202,405
Total Current Liabilities	128,490,065	63,438,700
Long-term bank loans, excluding current portion	40,000,000	30,000,000
Deferred income	2,832,781	3,003,895
Other liabilities	4,109,613	3,369,003
Total Liabilities	175,432,459	99,811,598
Stockholders' Equity	'	'
Common stock: par value $0.0001; 100,000,000 shares authorized; 27,716,316 and 27,341,744 shares issued at September 30, 2014 and December 31, 2013, respectively; 24,656,612 and 25,862,040 shares outstanding at September 30, 2014 and December 31, 2013, respectively	2,771	2,734
Additional paid-in capital	19,637,310	72,031,864
Treasury stock: 3,059,704 and 1,479,704 shares at September 30, 2014 and December 31, 2013, respectively, at cost	-76,570,621	-29,594,080
Retained earnings	231,803,243	173,744,551
Accumulated other comprehensive income	19,336,580	21,506,494
Total equity attributable to China Biologic Products, Inc.	194,209,283	237,691,563
Noncontrolling interest	64,175,844	66,278,046
Total Stockholders' Equity	258,385,127	303,969,609
Commitments and contingencies	'	'
Total Liabilities and Stockholders' Equity	$433,817,586	$403,781,207

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	27,716,316	27,341,744
Common Stock, Shares, Outstanding	24,656,612	25,862,040
Treasury Stock, Shares	3,059,704	1,479,704

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Sales	$68,923,830	$53,152,141	$185,264,391	$160,764,396
Cost of sales	22,356,577	17,165,897	58,991,724	49,904,917
Gross profit	46,567,253	35,986,244	126,272,667	110,859,479
Operating expenses	'	'	'	'
Selling expenses	2,420,971	2,551,245	8,032,632	6,829,365
General and administrative expenses	7,733,867	9,218,798	22,063,291	26,771,966
Research and development expenses	1,788,286	1,053,383	4,700,647	2,801,625
Income from operations	34,624,129	23,162,818	91,476,097	74,456,523
Other income (expenses)	'	'	'	'
Equity in (loss) income of an equity method investee	-84,516	642,579	1,776,063	1,382,524
Interest expense	-1,048,177	-306,656	-2,532,341	-741,569
Interest income	1,722,967	1,320,263	5,043,169	2,964,082
Total other income, net	590,274	1,656,186	4,286,891	3,605,037
Earnings before income tax expense	35,214,403	24,819,004	95,762,988	78,061,560
Income tax expense	7,007,650	4,871,041	16,832,025	13,223,592
Net income	28,206,753	19,947,963	78,930,963	64,837,968
Less: Net income attributable to noncontrolling interest	8,146,687	5,251,940	20,872,271	19,064,159
Net income attributable to China Biologic Products, Inc.	20,060,066	14,696,023	58,058,692	45,773,809
Net income per share of common stock:	'	'	'	'
Basic	$0.80	$0.55	$2.35	$1.71
Diluted	$0.76	$0.53	$2.24	$1.64
Weighted average shares used in computation:	'	'	'	'
Basic	24,548,042	26,288,154	24,325,752	26,649,563
Diluted	25,787,106	27,449,081	25,568,515	27,780,005
Net income	28,206,753	19,947,963	78,930,963	64,837,968
Other comprehensive income:	'	'	'	'
Foreign currency translation adjustment, net of nil income taxes	-125,450	1,985,434	-2,714,890	7,810,690
Comprehensive income	28,081,303	21,933,397	76,216,073	72,648,658
Less: Comprehensive income attributable to noncontrolling interest	8,081,309	5,586,905	20,327,295	20,469,852
Comprehensive income attributable to China Biologic Products, Inc.	$19,999,994	$16,346,492	$55,888,778	$52,178,806

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated other comprehensive income [Member]	Equity Attributable To China Biologic Products, Inc. [Member]	Noncontrolling Interest [Member]
Balance at Dec. 31, 2013	$303,969,609	$2,734	$72,031,864	$173,744,551	($29,594,080)	$21,506,494	$237,691,563	$66,278,046
Balance (in shares) at Dec. 31, 2013	'	27,341,744	'	'	'	'	'	'
Net income	78,930,963	0	0	58,058,692	0	0	58,058,692	20,872,271
Other comprehensive income	-2,714,890	0	0	0	0	-2,169,914	-2,169,914	-544,976
Share repurchase	-70,000,000	0	0	0	-70,000,000	0	-70,000,000	0
Share-based compensation	3,331,299	0	3,331,299	0	0	0	3,331,299	0
Excess tax benefits from stock option exercises	760,869	0	629,695	0	0	0	629,695	131,174
Common stock issued in connection with:	'	'	'	'	'	'	'	'
Exercise of stock options	2,258,285	27	2,258,258	0	0	0	2,258,285	0
Exercise of stock options (in shares)	'	269,947	'	'	'	'	'	'
Vesting of restricted shares	0	10	-10	0	0	0	0	0
Vesting of restricted shares (in shares)	'	104,625	'	'	'	'	'	'
Reissuance of treasury stock	33,212,518	0	10,189,059	0	23,023,459	0	33,212,518	0
Dividend declared to noncontrolling interest shareholders	-7,437,872	0	0	0	0	0	0	-7,437,872
Acquisition of noncontrolling interests	-83,925,654	0	-68,802,855	0	0	0	-68,802,855	-15,122,799
Balance at Sep. 30, 2014	$258,385,127	$2,771	$19,637,310	$231,803,243	($76,570,621)	$19,336,580	$194,209,283	$64,175,844
Balance (in shares) at Sep. 30, 2014	'	27,716,316	'	'	'	'	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income	$78,930,963	$64,837,968
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation	5,136,783	4,550,598
Amortization	558,991	1,027,650
Loss (gain) on sale of property, plant and equipment	152,638	-138,450
Reversal of allowance for doubtful accounts, net	-24,462	0
Allowance for doubtful accounts - other receivables and prepayments	0	37,453
Write-down of obsolete inventories	9,092	0
Deferred tax expense	934,986	428,037
Share-based compensation	3,331,299	4,076,817
Equity in income of an equity method investee	-1,776,063	-1,382,524
Excess tax benefits from share-based compensation arrangements	-760,869	0
Change in operating assets and liabilities:	'	'
Accounts receivable	-7,510,078	-10,758,305
Prepayment and other assets	-8,602,273	-720,340
Inventories	-8,705,670	-5,872,632
Accounts payable	396,647	1,254,404
Other payables and accrued expenses	1,866,112	1,088,481
Advance from customers	-1,364,123	-823,499
Due to related parties	-293,210	16,539
Income tax payable	1,827,163	837,760
Net cash provided by operating activities	64,107,926	58,459,957
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Payment for property, plant and equipment	-13,925,010	-17,076,459
Payment for intangible assets and land use right	-2,834,220	-1,141,197
Dividend received	0	560,980
Refund of deposits related to land use right	1,635,200	0
Proceeds upon maturity of time deposit	6,608,612	0
Proceeds from sale of property, plant and equipment	216,071	175,808
Net cash used in investing activities	-8,299,347	-17,480,868
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from stock option exercised	2,258,285	3,035,011
Proceeds from short term bank loans	44,500,340	4,808,400
Repayment of short term bank loans	-4,905,600	-8,014,000
Proceeds from long-term bank loans	70,000,000	30,000,000
Repayment of long-term bank loans	-33,700,000	0
Payment for deposits as security for long-term bank loans	-72,290,922	-30,000,000
Payment for deposit as security for short-term bank loan	-31,881,083	0
Proceeds from maturity of deposit as security for long-term bank loan	30,370,670	0
Payment for share repurchase	-70,000,000	-29,594,080
Net proceeds from reissuance of treasury stock	33,212,518	0
Acquisition of noncontrolling interest	-86,830,499	-1,963,913
Excess tax benefits from share-based compensation arrangements	760,869	0
Dividend paid by subsidiaries to noncontrolling interest shareholders	-6,035,226	-10,896,678
Net cash used in financing activities	-124,540,648	-42,625,260
EFFECTS OF FOREIGN EXCHANGE RATE CHANGE ON CASH	-827,626	3,533,528
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-69,559,695	1,887,357
Cash and cash equivalents at beginning of period	144,138,487	129,609,317
Cash and cash equivalents at end of period	74,578,792	131,496,674
Supplemental cash flow information	'	'
Cash paid for income taxes	14,098,003	11,957,795
Cash paid for interest expense	2,108,667	273,095
Noncash investing and financing activities:	'	'
Acquisition of property, plant and equipment included in payables	2,988,146	1,502,623
Transfer from prepayments to property, plant and equipment	$1,412,648	$7,607,160

BASIS_OF_PRESENTATION_SIGNIFIC

ACCOUNTS RECEIVABLE	9 Months Ended
	Sep. 30, 2014
Receivables [Abstract]	'
ACCOUNTS RECEIVABLE	'
	NOTE 2 – ACCOUNTS RECEIVABLE
	Accounts receivable at September 30, 2014 and December 31, 2013 consisted of the following:
		September 30, 2014	December 31, 2013
		USD	USD
	Accounts receivable	25,100,770	17,730,821
	Less: Allowance for doubtful accounts	-432,883	-460,689
	Total	24,667,887	17,270,132
	The activity in the allowance for doubtful accounts for the nine months ended September 30, 2014 and 2013 are as follows:
		For the nine months ended
		September 30, 2014	September 30, 2013
		USD	USD
	Beginning balance	460,689	415,607
	Provisions	6,211	-
	Recoveries	-30,673	-
	Write-offs	-	-
	Foreign currency translation adjustment	-3,344	11,261
	Ending balance	432,883	426,868

ACCOUNTS_RECEIVABLE

ACCOUNTS RECEIVABLE	9 Months Ended
	Sep. 30, 2014
Receivables [Abstract]	'
ACCOUNTS RECEIVABLE	'
	NOTE 2 – ACCOUNTS RECEIVABLE
	Accounts receivable at September 30, 2014 and December 31, 2013 consisted of the following:
		September 30, 2014	December 31, 2013
		USD	USD
	Accounts receivable	25,100,770	17,730,821
	Less: Allowance for doubtful accounts	-432,883	-460,689
	Total	24,667,887	17,270,132
	The activity in the allowance for doubtful accounts for the nine months ended September 30, 2014 and 2013 are as follows:
		For the nine months ended
		September 30, 2014	September 30, 2013
		USD	USD
	Beginning balance	460,689	415,607
	Provisions	6,211	-
	Recoveries	-30,673	-
	Write-offs	-	-
	Foreign currency translation adjustment	-3,344	11,261
	Ending balance	432,883	426,868

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
INVENTORIES	'
	NOTE 3 – INVENTORIES
	Inventories at September 30, 2014 and December 31, 2013 consisted of the following:
		September 30, 2014	December 31, 2013
		USD	USD
	Raw materials	51,032,796	47,400,578
	Work-in-process	26,039,984	20,720,666
	Finished goods	19,597,159	20,513,611
	Total	96,669,939	88,634,855
	No inventory write-down was recorded during the three months ended September 30, 2014 and 2013, respectively. An inventory write-down of $9,092 and nil was recorded for the nine months ended September 30, 2014 and 2013, respectively.

OTHER_RECEIVABLES_IN_RESPECT_O

OTHER RECEIVABLES IN RESPECT OF A HOUSING PROJECT	9 Months Ended
	Sep. 30, 2014
Other Income and Expenses [Abstract]	'
OTHER RECEIVABLES IN RESPECT OF A HOUSING PROJECT	'
	NOTE 4 –OTHER RECEIVABLES IN RESPECT OF A HOUSING PROJECT
	In 2009, 107 employees, or the Employee-participants, of Shandong Taibang entered into agreements, or the Housing Project Agreements, with a real estate developer regarding a housing development project, pursuant to which the developer agreed to develop and deliver residential units to the Employee-participants by the end of 2011 and the Employee-participants paid the developer deposits equal to 80% of the purchase prices of the residential units. To assist with their deposit payment, Shandong Taibang entered into separate agreements, or the Financial Assistance Agreements, with the Employee-participants and provided them with advances of up to 50% of the purchase prices of the residential units. These advances were to be repaid by deductions from the Employee-participants’ salaries. In addition, Shandong Taibang also entered into a purchase agreement with the developer to purchase additional units in the development project and made a deposit of RMB3,823,200 (approximately $621,270). However, the developer failed to deliver the residential units and is unlikely to be able to perform the Housing Project Agreements. In August 2014, the Company entered into agreements, or the Advance Payment Agreements, with the Employee-participants, pursuant to which the Company made advance payments to the Employee-participants equal to the deposits that the Employee-participants had paid the developer pursuant to the Housing Project Agreements and refunded them the deductions previously made from their salaries pursuant to the Financial Assistance Agreements together with accrued interest. As of September 30, 2014, the Company had made advance payments  totaling RMB30,894,884 (approximately $5,020,419) pursuant to the Advance Payment Agreements.

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
PROPERTY, PLANT AND EQUIPMENT	'
	NOTE 5 – PROPERTY, PLANT AND EQUIPMENT
	Property, plant and equipment at September 30, 2014 and December 31, 2013 consisted of the following:
		September 30, 2014	December 31, 2013
		USD	USD
	Buildings	32,210,958	31,714,173
	Machinery and equipment	53,272,420	36,919,094
	Furniture, fixtures, office equipment and vehicles	8,011,586	8,141,993
	Total property, plant and equipment, gross	93,494,964	76,775,260
	Accumulated depreciation	-29,112,130	-25,658,760
	Total property, plant and equipment, net	64,382,834	51,116,500
	Construction in progress	12,453,871	19,050,642
	Prepayment for property, plant and equipment	1,883,672	2,981,930
	Property, plant and equipment, net	78,720,377	73,149,072
	Depreciation expense for the three months ended September 30, 2014 and 2013 was $1,847,248 and $1,444,859, respectively. Depreciation expense for the nine months ended September 30, 2014 and 2013 was $5,136,783 and $4,550,598, respectively.

DEPOSITS_RELATED_TO_LAND_USE_R

DEPOSITS RELATED TO LAND USE RIGHTS	9 Months Ended
	Sep. 30, 2014
Deposits Related To Land Use Rights [Abstract]	'
DEPOSITS RELATED TO LAND USE RIGHTS	'
	NOTE 6 – DEPOSITS RELATED TO LAND USE RIGHTS
	In 2012, Guizhou Taibang made a refundable payment of RMB83,400,000 (approximately $13,552,500) to the local government in connection with the public bidding for a land use right in Guizhou Province. Given the decrease of the land area to be provided by the local government, RMB23,000,000 (approximately $3,737,500) was refunded by the local government. The remaining deposits will be refunded within one year following the completion of the bidding process.

RESTRICTED_CASH_AND_DEPOSIT

RESTRICTED CASH AND DEPOSIT	9 Months Ended
	Sep. 30, 2014
Restricted Cash and Investments [Abstract]	'
RESTRICTED CASH AND DEPOSIT	'
	NOTE 7 – RESTRICTED CASH AND DEPOSIT
	On August 7, 2013, the Company made a time deposit of RMB186,000,000 (approximately $30,225,000) with China Merchants Bank Beijing Branch (“CMB BJ Branch”) as a security for an 18-month US$30,000,000 loan lent by China Merchants Bank Co., Ltd., New York Branch (“CMB NY Branch”). In April 2014, due to the depreciation of RMB against USD, additional deposit of RMB1,000,000 (approximately $162,500) was made as security for this loan. In July 2014, the Company repaid the loan. The time deposit was released upon maturity in August 2014 accordingly.
	In February 2014, the Company made time deposits of RMB246,500,000 (approximately $40,056,250) and RMB194,600,000 (approximately $31,622,500) with CMB BJ Branch as a security for a 24-month $40,000,000 loan and an 18-month $30,000,000 loan respectively lent by CMB NY Branch (see Note 8).
	In August 2014, the Company made a time deposit of RMB196,300,000 (approximately $31,898,750) with CMB BJ Branch as a security for a 6-month RMB194,000,000 (approximately $31,525,000) loan lent by CMB BJ Branch (see Note 8).

BANK_LOANS

BANK LOANS	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
BANK LOANS	'
	NOTE 8 – BANK LOANS
	(a) Current
	The Company’s bank loans as of September 30, 2014 and December 31, 2013 consisted of the following:
		Maturity	Annual		September 30,	December 31,
	Loans	date	interest rate		2014	2013
					USD	USD
	Short-term bank loan, unsecured	12-May-14	6	%	-	4,911,000
	Short-term bank loan, unsecured	22-Dec-14	6	%	4,875,000	4,911,000
	Short-term bank loan, unsecured	9-Oct-14	5.6	%	13,000,000	-
	Short-term bank loan, secured	12-Feb-15	5.04	%	31,525,000	-
	Current portion of long-term bank loans	25-Aug-15	See note	(b)	26,300,000	-
	Total				75,700,000	9,822,000
	In August 2014, the Company entered into a credit facility agreement with CMB BJ Branch to finance the acquisition of additional equity interest in Guizhou Taibang (see Note 18). Pursuant to the facility agreement, the Company made an 6-month RMB194,000,000 (approximately $31,525,000) loan from CMB BJ Branch secured by a time deposit of RMB196,300,000 (approximately $31,898,750).
	Interest expense on short-term bank loans was $394,338 and $79,195 for the three months ended September 30, 2014 and 2013, respectively. Interest expense on short-term bank loans was $600,295 and $273,095 for the nine months ended September 30, 2014 and 2013, respectively.
	The Company did not have any revolving line of credit at September 30, 2014.
	(b) Non-current
		September 30, 2014	December 31, 2013
		USD	USD
	Long-term bank loans	66,300,000	30,000,000
	Less: current portion of long-term bank loans	26,300,000	-
	Total non-current bank loans	40,000,000	30,000,000
	On August 8, 2013, the Company entered into a credit facility agreement with CMB NY Branch to finance the share repurchase. Pursuant to the facility agreement, CMB NY Branch lends to the Company an 18-month $30,000,000 loan bearing an interest rate of 3-month LIBOR plus 1.6% per annum and a facility fee of 0.7% per annum. The loan is secured by a time deposit of RMB187,000,000 (approximately $30,387,500) held at CMB BJ Branch. The Company repaid the loan in July 2014.
	The Company entered into a credit facility agreement with CMB NY Branch on February 25, 2014 to finance the share repurchase (see Note 16). Pursuant to the facility agreement, CMB NY Branch lent to the Company a 24-month $40,000,000 loan and an 18-month $30,000,000 loan, secured by time deposits of RMB246,500,000 (approximately $40,056,250) and RMB194,600,000 (approximately $31,622,500), respectively, held at CMB BJ Branch. Both loans bear an interest rate of 3-month LIBOR plus 1.3% per annum and a facility fee of 1.2% per annum. In July 2014, the Company repaid $3,700,000 out of the 18-month $30,000,000 loan.

INCOME_TAX

INCOME TAX	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAX	'
	NOTE 9 – INCOME TAX
	On October 31, 2011, Shandong Taibang received a notice from the Shandong provincial government that the High and New Technology Enterprise qualification has been renewed for an additional three years which entitled it to a 15% preferential income tax rate from 2011 to 2013. Subject to reapplication, Shandong Taibang’s High-Tech Enterprise status will enable it to continue to enjoy the preferential income tax rate. Management believes that Shandong Taibang meets all the criteria for the reapplication of High-Tech Enterprise status.
	According to Cai Shui [2011] No. 58 dated July 27, 2011, Guizhou Taibang, being a qualified enterprise located in the western region of PRC, enjoys a preferential income tax rate of 15% effective retroactively from January 1, 2011 to December 31, 2020.
	The Company’s effective income tax rates were 20% and 20% for the three months ended September 30, 2014 and 2013, respectively. The Company’s effective income tax rates were 18% and 17% for nine months ended September 30, 2014 and 2013, respectively.
	As of and for the nine months ended September 30, 2014, the Company did not have any unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits to change significantly within the next 12 months.

OPTIONS_AND_NONVESTED_SHARES

OPTIONS AND NONVESTED SHARES	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
OPTIONS AND NONVESTED SHARES	'
	NOTE 10 – OPTIONS AND NONVESTED SHARES
	Options
	A summary of stock options activity for the nine months ended September 30, 2014 is as follow:
		Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual	Aggregate Intrinsic
				Term in Years	Value
			USD		USD
	Outstanding at December 31, 2013	1,882,376	9.98	7.2	35,518,897
	Granted	-	-
	Exercised	-269,947	8.37		9,409,238
	Forfeited and expired	-32,920	11.44
	Outstanding at September 30, 2014	1,579,509	10.23	6.67	69,077,427
	Vested and expected to vest	1,579,509	10.23	6.67	69,077,427
	Exercisable at September 30, 2014	1,262,009	10.36	6.41	55,026,002
	For the three months ended September 30, 2014 and 2013, the Company recorded stock compensation expense of $394,769 and $651,047, respectively, in general and administrative expenses. For the nine months ended September 30, 2014 and 2013, the Company recorded stock compensation expense of $1,249,663 and $3,346,046, respectively, in general and administrative expenses.
	At September 30, 2014, approximately $2,313,967 of stock compensation expense with respect to the non-vested stock options is expected to be recognized over approximately 1.65 years.
	Nonvested shares
	A summary of nonvested shares activity for the nine months ended September 30, 2014 is as follows:
		Number of nonvested shares	Grant date weighted average fair value
			USD
	Outstanding at December 31, 2013	362,750	20.91
	Granted	294,000	51.74
	Vested	-104,625	20.47
	Forfeited	-2,500	9.85
	Outstanding at September 30, 2014	549,625	37.53
	For the three months ended September 30, 2014 and 2013, the Company recorded stock compensation expense of $974,601 and $377,808 respectively in general and administrative expenses. For the nine months ended September 30, 2014 and 2013, the Company recorded stock compensation expense of $2,081,636 and $730,771 respectively in general and administrative expenses.
	At September 30, 2014, approximately $19,830,214 of stock compensation expense with respect to nonvested shares is expected to be recognized over approximately 3.11 years.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	NOTE 11 – FAIR VALUE MEASUREMENTS
	Management used the following methods and assumptions to estimate the fair value of financial instruments at the relevant balance sheet dates:
	• Short-term financial instruments (including cash and cash equivalents, time deposit, restricted deposits, accounts receivable, other receivables, short-term bank loans including current portion of long-term bank loans, accounts payable, other payables and accrued expenses, and amount due to related parties) – The carrying amounts of the short-term financial instruments approximate their fair values because of the short maturity of these instruments.
	• Restricted cash and deposit, excluding current portion – The carrying amounts of the restricted cash and deposit approximate their fair value. The fair value is estimated using discounted cash flow analysis based on the Company’s incremental borrowing rates for similar borrowing.
	• Long-term bank loan excluding current portion of long-term bank loans– fair value is based on the amount of future cash flows associated with the long-term bank loan discounted at the Company’s current borrowing rate for similar debt instruments of comparable terms. The carrying value of the long-term bank loan approximate its fair value as the long-term bank loan carry variable interest rate which approximate rate currently offered by the Company’s bankers for similar debt instruments of comparable maturities.

SALES

SALES	9 Months Ended
	Sep. 30, 2014
Sales [Abstract]	'
SALES	'
	NOTE 12 – SALES
	The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. The Company’s sales by significant types of product for the three months ended September 30, 2014 and 2013 are as follows:
		For the three months ended
		September 30, 2014	September 30, 2013
		USD	USD
	Human Albumin	26,367,969	26,420,902
	Immunoglobulin products:
	Human Immunoglobulin for Intravenous Injection	28,732,092	17,162,545
	Other Immunoglobulin products	4,140,522	5,355,020
	Placenta Polypeptide	7,810,546	2,762,092
	Others	1,872,701	1,451,582
	Total	68,923,830	53,152,141
	The Company’s sales by significant types of product for the nine months ended September 30, 2014 and 2013 are as follows:
		For the nine months ended
		September 30, 2014	September 30, 2013
		USD	USD
	Human Albumin	70,639,862	69,686,924
	Immunoglobulin products:
	Human Immunoglobulin for Intravenous Injection	75,707,888	63,921,570
	Other Immunoglobulin products	17,417,328	15,949,006
	Placenta Polypeptide	17,545,609	7,984,246
	Others	3,953,704	3,222,650
	Total	185,264,391	160,764,396

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 13 – COMMITMENTS AND CONTINGENCIES
	Capital commitments
	At September 30, 2014, commitments outstanding for the purchase of property, plant and equipment approximated $5,050,000.
	Legal proceedings
	Dispute among Guizhou Taibang Shareholders over Raising Additional Capital
	In May 2007, a 91% majority of Guizhou Taibang’s shareholders approved a plan to raise additional capital from private strategic investors through the issuance of an additional 20,000,000 shares of Guizhou Taibang at RMB2.80 per share. The plan required all existing Guizhou Taibang shareholders to waive their rights of first refusal to subscribe for the additional shares. The remaining 9% minority shareholder of Guizhou Taibang’s shares, Guizhou Jie’an Company, or Jie’an, did not support the plan and did not waive its right of first refusal. In May 2007, the majority shareholders caused Guizhou Taibang to sign an Equity Purchase Agreement with certain investors, pursuant to which the investors agreed to invest an aggregate of $7,475,832 (or RMB50,960,000) in exchange for 18,200,000 shares, or 21.4%, of Guizhou Taibang’s equity interests. At the same time, Jie’an also subscribed for 1,800,000 shares, representing its pro rata share of the 20,000,000 shares being offered. The proceeds from all parties were received by Guizhou Taibang in accordance with the agreement.
	In June 2007, Jie’an brought suit in the High Court of Guizhou province, China, against Guizhou Taibang and the three other original shareholders of Guizhou Taibang, alleging the illegality of the Equity Purchase Agreement. In its complaint, Jie’an claimed that it had a right to acquire the 18,200,000 shares offered to the strategic investors under the Equity Purchase Agreement. In September 2008, the Guizhou High Court ruled against Jie’an and sustained the Equity Purchase Agreement. In November 2008, Jie’an appealed the Guizhou High Court judgment to the People’s Supreme Court in Beijing. In May 2009, the People’s Supreme Court sustained the original ruling and denied the rights of first refusal of Jie’an over the 18,200,000 shares.
	During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital injection with the local Administration for Industry and Commerce, or AIC, pursuant to the Equity Purchase Agreement, and such request was approved by the majority shareholders of Guizhou Taibang in a shareholders meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request, pending the outcome of the ongoing litigation. In March 2012, the Company received a subpoena that Jie’an brought suit in the People’s Court of Huaxi District, Guizhou Province, against Guizhou Taibang, alleging Guizhou Taibang’s withholding of its request. Jie’an requested that Guizhou Taibang register its 1.8 million shares of capital injection, pay dividends associated with these shares, as well as the related interest and penalty from May 2007 to December 2011 amounting to $3,967,500 (or RMB25,000,000) in aggregate, and return the over-paid subscription of $228,528 (or RMB1,440,000), as well as the interest and penalty, amounting to $1,587,000 (or RMB10,000,000) in aggregate. The People’s Court of Huaxi District, Guizhou Province, has accepted Jie’an’s suit. In May 2012, Guizhou Taibang was informed by the court that the case was postponed upon the request from Jie’an. In July 2013, the People’s Court of Huaxi District issued an order declaring that the suit shall be set aside because the court has no jurisdiction over the suit. Jie’an did not appeal the case to the upper-level court.
	In December 2013, Jie’an brought suit again in the People’s Court of Huaxi District, Guizhou Province, against Guizhou Taibang, alleging that Guizhou Taibang withheld Jie’an’s request to register 1.8 million shares under its name with the local AIC. The People’s Court of Huaxi District, Guizhou Province, accepted Jie’an’s suit and heard the case on February 26, 2014. In July 2014, the People’s Court of Huaxi District ruled against Jie’an, denying its request to register such shares. However, as part of its ruling, the People’s Court of Huaxi District ordered the Company to pay dividends of $2,240,542 (or RMB 13,809,197) associated with these shares and the related interest expenses to Jie’an. Both the Company and Jie’an appealed the case to the upper-level court in July 2014. As this case should be closely tied to the outcome of the strategic investors’ dispute stated below, the Company does not expect Jie’an to prevail.
	In November 2013, Guizhou Taibang held a shareholders meeting and the shareholders passed resolutions, or the November 2013 Resolutions, that, inter alia, (i) determined that it was no longer necessary for Guizhou Taibang to obtain additional capital from investors; (ii) rejected Jie'an's request that Jie'an subscribe for additional shares of Guizhou Taibang alone and one or more other shareholders reduce their shareholding in Guizhou Taibang; and (iii) approved the issuance of a total of 20,000,000 new shares to all existing shareholders on a pro rata basis. In December 2013, in addition to its lawsuit against Guizhou Taibang for Guizhou Taibang's failure to register its purchase of 1,800,000 shares in 2007 with the local AIC before the People's Court of Huaxi District, Guiyang, Jie'an filed another lawsuit against Guizhou Taibang with the People’s Court of Huaxi District and requested that the court declare the November 2013 Resolutions void. The case was heard on March 6, 2014. In July 2014, the People’s Court of Huaxi District ruled against Jie’an denying its request to declare the Resolutions void. Jie’an appealed the case to the upper-level court on July 28, 2014. The Company does not expect Jie’an to prevail. In March 2014, Guizhou Taibang held a shareholders meeting and the shareholders passed resolutions, or the March 2014 Resolutions, that, inter alia, recalculated the ownership percentage in Guizhou Taibang based on the November 2013 Resolutions and the additional capital injections from existing shareholders. Guizhou Taibang updated the registration with the local AIC regarding the additional capital injections in August 2014. In September 2014, Jie’an and Yigong Shengda Technology Company Limited, or Yigong, another minority shareholder of Guizhou Taibang, appealed to People’s Court of Huaxi District and requested that the court declare both the November 2013 Resolutions and the March 2014 Resolutions void and instruct Guizhou Taibang to withdraw the AIC registration regarding the additional capital injections. The Company does not expect Jie’an or Yigong to prevail.
	If the Company decides to ratify the approval or the case is ruled in Jie’an’s favor, Dalin’s ownership in Guizhou Taibang will be diluted to 71% and Jie’an may be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date on which Jie’an’s capital contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated below, the Company does not expect Jie’an to prevail. As of September 30, 2014, the Company had recorded, in its balance sheet, payables to Jie’an in the amounts of RMB5,040,000 (approximately $819,000) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $234,000) for the over-paid subscription and RMB3,235,544 (approximately $525,776) for the accrued interest.
	As a result of this dispute, the strategic investors’ equity ownership in Guizhou Taibang and the related increase in registered capital of Guizhou Taibang have not been registered with the local AIC. In January 2010, the strategic investors brought suit in the High Court of Guizhou Province against Guizhou Taibang alleging Guizhou Taibang’s failure to register their equity interest in Guizhou Taibang with the local AIC and requesting the distribution of their share of Guizhou Taibang’s dividends declared since 2007. Dalin was also joined as a co-defendant as it is the majority shareholder and exercises control over Guizhou Taibang’s day-to-day operations.
	In October, 2010, the High Court of Guizhou ruled in favor of the Company and denied the strategic investors’ right as shareholders of Guizhou Taibang, as well as their entitlement to the dividends. In light of this ruling, the Company returned the proceeds of $1,699,040 (or RMB11,200,000) to one of the strategic investors in November 2010. In October 2010, the other strategic investors appealed to the PRC Supreme Court in Beijing on the ruling of the High Court of Guizhou. The PRC Supreme Court overruled the decision of the High Court of Guizhou and remanded the case to the High Court of Guizhou for retrial. In January 2012, the strategic investors re-filed their case to the High Court of Guizhou requesting, in addition to the share distribution, the distribution of dividends and interest in the amount of RMB18,349,345 (approximately $2,981,769) and RMB2,847,000 (approximately $462,638), respectively. In December 2012, the High Court of Guizhou affirmed the judgment against the strategic investors. In January 2013, the strategic investors appealed to the PRC Supreme Court on the ruling again and the appeal was accepted.
	In September 2013, the PRC Supreme Court made the final judgment against the strategic investors and denied the strategic investors’ right as shareholders of Guizhou Taibang and their claim for the related dividend distribution. In November 2013, the strategic investors requested the PRC Supreme Court to reconsider the judgment and such request was rejected by the PRC Supreme Court on January 17, 2014. As of September 30, 2014, Guizhou Taibang had made provision for the strategic investors’ initial fund along with RMB19,003,712 (approximately $3,088,103) in accrued interest, and RMB509,600 (approximately $82,810) for the 1% penalty imposed by the agreement for any breach in the event that Guizhou Taibang is required to return their original investment amount to the strategic investors.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	NOTE 14 – RELATED PARTY TRANSACTIONS
	The material related party transactions undertaken by the Company with related parties for the three months ended September 30, 2014 and 2013 are presented as follows:
			For the three months ended
			September 30, 2014		September 30, 2013
			USD		USD
	Commission expenses with related parties(1)			-		815,410
	The material related party transactions undertaken by the Company with related parties for the nine months ended September 30, 2014 and 2013 are presented as follows:
			For the nine months ended
			September 30, 2014		September 30, 2013
			USD		USD
	Commission expenses with related parties(1)			2,249,716		2,367,722
	The related party balances as at September 30, 2014 and December 31, 2013 are presented as follows:
	Liabilities		Purpose		September 30, 2014		December 31, 2013
					USD		USD
	Other payable – a related party(1)			Commission		8,125		351,955
	Other payable – a related party(2)			Loan		2,366,000		2,383,472
	Other payable – a related party(3)			Contribution		-		2,929,903
	Other payable – related parties(4)			Contribution		1,578,776		1,541,640
	Total other payable – related parties					3,952,901		7,206,970
		-1	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Pharmaceutical Co., Ltd. (“Guizhou Eakan”), one of the former Guizhou Taibang’s noncontrolling interest shareholders (see note 18), pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. The agency contract expired on May 31, 2014 and Guizhou Eakan no longer provided the promotion services thereafter. At September 30, 2014 and December 31, 2013, Guizhou Taibang accrued commission payable of $8,125 and $351,955 for service rendered by Guizhou Eakan, respectively. For the three months ended September 30, 2014 and 2013, commission expense for service rendered by Guizhou Eakan was nil and $815,410, respectively. For the nine months ended September 30, 2014 and 2013, commission expense for service rendered by Guizhou Eakan was $2,249,716 and $2,367,722, respectively.
		-2	Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,366,000 and $2,383,472 at September 30, 2014 and December 31, 2013, respectively. Guizhou Eakan Investing Corp. is an affiliate of Guizhou Eakan. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand.
		-3	In December 2013, Guizhou Taibang received a contribution of RMB17,898,000 (approximately $2,908,425) from Guizhou Eakan, pending for the registration with the local AIC. In August 2014, the Company acquired the equity interest owned by Guizhou Eakan in Guizhou Taibang and made the registration accordingly.
		-4	Guizhou Taibang has payables to Jie’an, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $1,578,776 and $1,541,640 at September 30, 2014 and December 31, 2013, respectively. In 2007, Guizhou Taibang received additional contributions from Jie’an of $962,853 (or RMB6,480,000) to maintain Jie’an’s equity interest in Guizhou Taibang at 9%. However, due to a legal dispute among shareholders over raising additional capital as discussed in the legal proceeding section (see Note 13), the contribution is subject to be returned to Jie’an. During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC, pursuant to the Equity Purchase Agreement, and such registration was approved by the majority shareholders of Guizhou Taibang in a shareholders’ meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request until the completion of the ongoing litigations. If the Company decided to ratify the approval, Dalin’s ownership in Guizhou Taibang will be diluted to 71% and Jie’an will be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date on which Jie’an’s contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated above, the Company has recorded, in its balance sheet, payables to Jie’an in the amounts of RMB5,040,000 (approximately $819,000) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $234,000) for the over-paid subscription and RMB3,235,544 (approximately $525,776) for the accrued interest and penalty at September 30, 2014.

NET_INCOME_PER_SHARE

NET INCOME PER SHARE	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
NET INCOME PER SHARE	'
	NOTE 15 - NET INCOME PER SHARE
	The following table sets forth the computation of basic and diluted net income per share for the periods indicated:
		For the three months ended
		September 30, 2014		September 30, 2013
		USD		USD
	Net income attributable to China Biologic Products, Inc.		20,060,066		14,696,023
	Earnings allocated to participating nonvested shares		-342,190		-143,220
	Net income used in basic/diluted net income per common stock		19,717,876		14,552,803
	Weighted average shares used in computing basic net income per common stock		24,548,042		26,288,154
	Diluted effect of stock option		1,239,064		1,160,927
	Weighted average shares used in computing diluted net income per common stock		25,787,106		27,449,081
	Net income per common stock – basic		0.8		0.55
	Net income per common stock – diluted		0.76		0.53
	During the three months ended September 30, 2014 and 2013, no option was antidilutive and excluded from the calculation of diluted net income per common stock.
	The following table sets forth the computation of basic and diluted net income per share for the periods indicated:
		For the nine months ended
		September 30, 2014		September 30, 2013
		USD		USD
	Net income attributable to China Biologic Products, Inc.		58,058,692		45,773,809
	Earnings allocated to participating nonvested shares		-895,840		-303,490
	Net income used in basic/diluted net income per common stock		57,162,852		45,470,319
	Weighted average shares used in computing basic net income per common stock		24,325,752		26,649,563
	Diluted effect of stock option		1,242,763		1,130,442
	Weighted average shares used in computing diluted net income per common stock		25,568,515		27,780,005
	Net income per common stock – basic		2.35		1.71
	Net income per common stock – diluted		2.24		1.64
	During the nine months ended September 30, 2014 and 2013, no option was antidilutive and excluded from the calculation of diluted net income per common stock.

SHARE_REPURCHASE

SHARE REPURCHASE	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
SHARE REPURCHASE	'
	NOTE 16 – SHARE REPURCHASE
	On January 27, 2014, the Company entered into a redemption agreement with one of its individual shareholders, pursuant to which the Company repurchased 2,500,000 shares of common stock for a consideration of $70,000,000. The transaction was completed on February 28, 2014.

FOLLOWON_OFFERING_OF_COMMON_ST

FOLLOW-ON OFFERING OF COMMON STOCK	9 Months Ended
	Sep. 30, 2014
Follow on Offering of Common Stock [Abstract]	'
FOLLOW-ON OFFERING OF COMMON STOCK	'
	NOTE 17 – FOLLOW-ON OFFERING OF COMMON STOCK
	On July 2, 2014, the Company completed a follow-on offering of 1,782,500 shares of common stock at a price of $38.00 per share, less the underwriting discounts and commissions and offering expenses. In this July 2014 follow-on offering, the Company sold 920,000 shares (including 120,000 shares sold pursuant to the exercise by the underwriters of their option to purchase additional shares from the Company) and a selling stockholder sold 862,500 shares (including 112,500 shares sold pursuant to the exercise by the underwriters of their option to purchase additional shares from such selling stockholder). The Company raised net proceeds of approximately $33.2 million from this offering, after deducting the underwriting discounts and commissions and offering expenses payable by the Company. The Company did not receive any proceeds from the sale of the shares by the selling stockholder.

ACQUISITION_OF_ADDITIONAL_EQUI

ACQUISITION OF ADDITIONAL EQUITY INTEREST IN GUIZHOU TAIBANG	9 Months Ended
	Sep. 30, 2014
Equity Method Investments and Joint Ventures [Abstract]	'
ACQUISITION OF ADDITIONAL EQUITY INTEREST IN GUIZHOU TAIBANG	'
	NOTE 18 – ACQUISITION OF ADDITIONAL EQUITY INTEREST IN GUIZHOU TAIBANG
	On August 25, 2014, Guiyang Dalin Biotechnology ("Guiyang Dalin"), a wholly-owned subsidiary of the Company, entered into an agreement to acquire an additional 19.84% equity interest in Guizhou Taibang from Guizhou Eakan, a non-controlling interest shareholder of Guizhou Taibang. The total consideration of the transaction was RMB535 million (approximately $86.9 million). The Company completed the acquisition on September 4, 2014 and increased its equity interest in Guizhou Taibang to 76.23%.

ACCOUNTS_RECEIVABLE_Tables

ACCOUNTS RECEIVABLE (Tables)	9 Months Ended
	Sep. 30, 2014
Receivables [Abstract]	'
SCHEDULE OF ACCOUNTS RECEIVABLE	'
	Accounts receivable at September 30, 2014 and December 31, 2013 consisted of the following:
		September 30, 2014	December 31, 2013
		USD	USD
	Accounts receivable	25,100,770	17,730,821
	Less: Allowance for doubtful accounts	-432,883	-460,689
	Total	24,667,887	17,270,132
SCHEDULE OF ACTIVITIES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS	'
	The activity in the allowance for doubtful accounts for the nine months ended September 30, 2014 and 2013 are as follows:
		For the nine months ended
		September 30, 2014	September 30, 2013
		USD	USD
	Beginning balance	460,689	415,607
	Provisions	6,211	-
	Recoveries	-30,673	-
	Write-offs	-	-
	Foreign currency translation adjustment	-3,344	11,261
	Ending balance	432,883	426,868

INVENTORIES_Tables

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
SCHEDULE OF INVENTORIES	'
	Inventories at September 30, 2014 and December 31, 2013 consisted of the following:
		September 30, 2014	December 31, 2013
		USD	USD
	Raw materials	51,032,796	47,400,578
	Work-in-process	26,039,984	20,720,666
	Finished goods	19,597,159	20,513,611
	Total	96,669,939	88,634,855

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT	'
	Property, plant and equipment at September 30, 2014 and December 31, 2013 consisted of the following:
		September 30, 2014	December 31, 2013
		USD	USD
	Buildings	32,210,958	31,714,173
	Machinery and equipment	53,272,420	36,919,094
	Furniture, fixtures, office equipment and vehicles	8,011,586	8,141,993
	Total property, plant and equipment, gross	93,494,964	76,775,260
	Accumulated depreciation	-29,112,130	-25,658,760
	Total property, plant and equipment, net	64,382,834	51,116,500
	Construction in progress	12,453,871	19,050,642
	Prepayment for property, plant and equipment	1,883,672	2,981,930
	Property, plant and equipment, net	78,720,377	73,149,072

BANK_LOANS_Tables

BANK LOANS (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
SCHEDULE OF SHORT-TERM BANK LOANS	'
	The Company’s bank loans as of September 30, 2014 and December 31, 2013 consisted of the following:
		Maturity	Annual		September 30,	December 31,
	Loans	date	interest rate		2014	2013
					USD	USD
	Short-term bank loan, unsecured	12-May-14	6	%	-	4,911,000
	Short-term bank loan, unsecured	22-Dec-14	6	%	4,875,000	4,911,000
	Short-term bank loan, unsecured	9-Oct-14	5.6	%	13,000,000	-
	Short-term bank loan, secured	12-Feb-15	5.04	%	31,525,000	-
	Current portion of long-term bank loans	25-Aug-15	See note	(b)	26,300,000	-
	Total				75,700,000	9,822,000
SCHDULE OF NON-CURRENT LONG TERM BANK LOANS	'
	The Company did not have any revolving line of credit at September 30, 2014.
	(b) Non-current
		September 30, 2014	December 31, 2013
		USD	USD
	Long-term bank loans	66,300,000	30,000,000
	Less: current portion of long-term bank loans	26,300,000	-
	Total non-current bank loans	40,000,000	30,000,000

OPTIONS_AND_NONVESTED_SHARES_T

OPTIONS AND NONVESTED SHARES (Tables)	9 Months Ended
	Sep. 30, 2014
Options and Nonvested Shares [Abstract]	'
SCHEDULE OF STOCK OPTIONS ACTIVITY	'
	A summary of stock options activity for the nine months ended September 30, 2014 is as follow:
		Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual	Aggregate Intrinsic
				Term in Years	Value
			USD		USD
	Outstanding at December 31, 2013	1,882,376	9.98	7.2	35,518,897
	Granted	-	-
	Exercised	-269,947	8.37		9,409,238
	Forfeited and expired	-32,920	11.44
	Outstanding at September 30, 2014	1,579,509	10.23	6.67	69,077,427
	Vested and expected to vest	1,579,509	10.23	6.67	69,077,427
	Exercisable at September 30, 2014	1,262,009	10.36	6.41	55,026,002
SCHEDULE OF NONVESTED SHARES ACTIVITY	'
	A summary of nonvested shares activity for the nine months ended September 30, 2014 is as follows:
		Number of nonvested shares	Grant date weighted average fair value
			USD
	Outstanding at December 31, 2013	362,750	20.91
	Granted	294,000	51.74
	Vested	-104,625	20.47
	Forfeited	-2,500	9.85
	Outstanding at September 30, 2014	549,625	37.53

SALES_Tables

SALES (Tables)	9 Months Ended
	Sep. 30, 2014
Sales Disclosure [Abstract]	'
SCHEDULE OF SALES BY PRODUCT TYPE	'
	The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. The Company’s sales by significant types of product for the three months ended September 30, 2014 and 2013 are as follows:
		For the three months ended
		September 30, 2014	September 30, 2013
		USD	USD
	Human Albumin	26,367,969	26,420,902
	Immunoglobulin products:
	Human Immunoglobulin for Intravenous Injection	28,732,092	17,162,545
	Other Immunoglobulin products	4,140,522	5,355,020
	Placenta Polypeptide	7,810,546	2,762,092
	Others	1,872,701	1,451,582
	Total	68,923,830	53,152,141
	The Company’s sales by significant types of product for the nine months ended September 30, 2014 and 2013 are as follows:
		For the nine months ended
		September 30, 2014	September 30, 2013
		USD	USD
	Human Albumin	70,639,862	69,686,924
	Immunoglobulin products:
	Human Immunoglobulin for Intravenous Injection	75,707,888	63,921,570
	Other Immunoglobulin products	17,417,328	15,949,006
	Placenta Polypeptide	17,545,609	7,984,246
	Others	3,953,704	3,222,650
	Total	185,264,391	160,764,396

RELATED_PARTY_TRANSACTIONS_Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
SCHEDULE OF RELATED PARTY TRANSACTION	'
	The material related party transactions undertaken by the Company with related parties for the three months ended September 30, 2014 and 2013 are presented as follows:
			For the three months ended
			September 30, 2014		September 30, 2013
			USD		USD
	Commission expenses with related parties(1)			-		815,410
	The material related party transactions undertaken by the Company with related parties for the nine months ended September 30, 2014 and 2013 are presented as follows:
			For the nine months ended
			September 30, 2014		September 30, 2013
			USD		USD
	Commission expenses with related parties(1)			2,249,716		2,367,722
		-1	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Pharmaceutical Co., Ltd. (“Guizhou Eakan”), one of the former Guizhou Taibang’s noncontrolling interest shareholders (see note 18), pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. The agency contract expired on May 31, 2014 and Guizhou Eakan no longer provided the promotion services thereafter. At September 30, 2014 and December 31, 2013, Guizhou Taibang accrued commission payable of $8,125 and $351,955 for service rendered by Guizhou Eakan, respectively. For the three months ended September 30, 2014 and 2013, commission expense for service rendered by Guizhou Eakan was nil and $815,410, respectively. For the nine months ended September 30, 2014 and 2013, commission expense for service rendered by Guizhou Eakan was $2,249,716 and $2,367,722, respectively.
SCHEDULE OF RELATED PARTY TRANSACTIONS	'
	The related party balances as at September 30, 2014 and December 31, 2013 are presented as follows:
	Liabilities		Purpose		September 30, 2014		December 31, 2013
					USD		USD
	Other payable – a related party(1)			Commission		8,125		351,955
	Other payable – a related party(2)			Loan		2,366,000		2,383,472
	Other payable – a related party(3)			Contribution		-		2,929,903
	Other payable – related parties(4)			Contribution		1,578,776		1,541,640
	Total other payable – related parties					3,952,901		7,206,970
		-1	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Pharmaceutical Co., Ltd. (“Guizhou Eakan”), one of the former Guizhou Taibang’s noncontrolling interest shareholders (see note 18), pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. The agency contract expired on May 31, 2014 and Guizhou Eakan no longer provided the promotion services thereafter. At September 30, 2014 and December 31, 2013, Guizhou Taibang accrued commission payable of $8,125 and $351,955 for service rendered by Guizhou Eakan, respectively. For the three months ended September 30, 2014 and 2013, commission expense for service rendered by Guizhou Eakan was nil and $815,410, respectively. For the nine months ended September 30, 2014 and 2013, commission expense for service rendered by Guizhou Eakan was $2,249,716 and $2,367,722, respectively.
		-2	Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,366,000 and $2,383,472 at September 30, 2014 and December 31, 2013, respectively. Guizhou Eakan Investing Corp. is an affiliate of Guizhou Eakan. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand.
		-3	In December 2013, Guizhou Taibang received a contribution of RMB17,898,000 (approximately $2,908,425) from Guizhou Eakan, pending for the registration with the local AIC. In August 2014, the Company acquired the equity interest owned by Guizhou Eakan in Guizhou Taibang and made the registration accordingly.
		-4	Guizhou Taibang has payables to Jie’an, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $1,578,776 and $1,541,640 at September 30, 2014 and December 31, 2013, respectively. In 2007, Guizhou Taibang received additional contributions from Jie’an of $962,853 (or RMB6,480,000) to maintain Jie’an’s equity interest in Guizhou Taibang at 9%. However, due to a legal dispute among shareholders over raising additional capital as discussed in the legal proceeding section (see Note 13), the contribution is subject to be returned to Jie’an. During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC, pursuant to the Equity Purchase Agreement, and such registration was approved by the majority shareholders of Guizhou Taibang in a shareholders’ meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request until the completion of the ongoing litigations. If the Company decided to ratify the approval, Dalin’s ownership in Guizhou Taibang will be diluted to 71% and Jie’an will be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date on which Jie’an’s contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated above, the Company has recorded, in its balance sheet, payables to Jie’an in the amounts of RMB5,040,000 (approximately $819,000) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $234,000) for the over-paid subscription and RMB3,235,544 (approximately $525,776) for the accrued interest and penalty at September 30, 2014.

NET_INCOME_PER_SHARE_Tables

NET INCOME PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2014
Net Income Loss Per Share Disclosure [Abstract]	'
SCHEDULE OF EPS - BASIC AND DILUTED	'
	The following table sets forth the computation of basic and diluted net income per share for the periods indicated:
		For the three months ended
		September 30, 2014		September 30, 2013
		USD		USD
	Net income attributable to China Biologic Products, Inc.		20,060,066		14,696,023
	Earnings allocated to participating nonvested shares		-342,190		-143,220
	Net income used in basic/diluted net income per common stock		19,717,876		14,552,803
	Weighted average shares used in computing basic net income per common stock		24,548,042		26,288,154
	Diluted effect of stock option		1,239,064		1,160,927
	Weighted average shares used in computing diluted net income per common stock		25,787,106		27,449,081
	Net income per common stock – basic		0.8		0.55
	Net income per common stock – diluted		0.76		0.53
	The following table sets forth the computation of basic and diluted net income per share for the periods indicated:
		For the nine months ended
		September 30, 2014		September 30, 2013
		USD		USD
	Net income attributable to China Biologic Products, Inc.		58,058,692		45,773,809
	Earnings allocated to participating nonvested shares		-895,840		-303,490
	Net income used in basic/diluted net income per common stock		57,162,852		45,470,319
	Weighted average shares used in computing basic net income per common stock		24,325,752		26,649,563
	Diluted effect of stock option		1,242,763		1,130,442
	Weighted average shares used in computing diluted net income per common stock		25,568,515		27,780,005
	Net income per common stock – basic		2.35		1.71
	Net income per common stock – diluted		2.24		1.64

BASIS_OF_PRESENTATION_SIGNIFIC1

BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Basis Of Presentation Significant Concentration And Risk [Line Items]	'	'	'	'	'
Total cash at banks and deposits including insured amount	$177,537,107	'	$177,537,107	'	$180,858,848
Cash, Insured Amount	$184,316	'	$184,316	'	$679,022
Customers that individually comprised 10% or more of the total sales	0	0	0	0	'
Suppliers that comprised 10% or more of the total purchases	0	0	0	0	'
Customers represented 10% or more of trade receivables	0	'	0	'	0
Suppliers that represented more than 10% of accounts payables	0	'	0	'	0
Human Albumin [Member]	'	'	'	'	'
Basis Of Presentation Significant Concentration And Risk [Line Items]	'	'	'	'	'
Major product sales percentage	38.30%	49.70%	38.10%	43.30%	'
Human Immunoglobulin For Intravenous Injection [Member]	'	'	'	'	'
Basis Of Presentation Significant Concentration And Risk [Line Items]	'	'	'	'	'
Major product sales percentage	41.70%	32.30%	40.90%	39.80%	'

SCHEDULE_OF_ACCOUNTS_RECEIVABL

SCHEDULE OF ACCOUNTS RECEIVABLE (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable	$25,100,770	$17,730,821
Less: Allowance for doubtful accounts	-432,883	-460,689
Total	$24,667,887	$17,270,132

SCHEDULE_OF_ACTIVITIES_IN_ALLO

SCHEDULE OF ACTIVITIES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'
Beginning balance	$460,689	$415,607
Provisions	6,211	0
Recoveries	-30,673	0
Write-offs	0	0
Foreign currency translation adjustment	-3,344	11,261
Ending balance	$432,883	$426,868

SCHEDULE_OF_INVENTORIES_Detail

SCHEDULE OF INVENTORIES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Raw materials	$51,032,796	$47,400,578
Work-in-process	26,039,984	20,720,666
Finished goods	19,597,159	20,513,611
Total	$96,669,939	$88,634,855

INVENTORIES_Narrative_Details

INVENTORIES (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Write-down of obsolete inventories	$0	$0	$9,092	$0

OTHER_RECEIVABLES_IN_RESPECT_O1

OTHER RECEIVABLES IN RESPECT OF A HOUSING PROJECT (Narrative) (Details)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
	USD ($)	CNY
Other Receivables [Line Items]	'	'
Repayments of Deposits and Interest Expenses	$5,020,419	30,894,884
Deposits	$621,270	3,823,200

SCHEDULE_OF_PROPERTY_PLANT_AND

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Total property, plant and equipment, gross	$93,494,964	$76,775,260
Accumulated depreciation	-29,112,130	-25,658,760
Total property, plant and equipment, net	64,382,834	51,116,500
Construction in progress	12,453,871	19,050,642
Prepayment for property, plant and equipment	1,883,672	2,981,930
Property, plant and equipment, net	78,720,377	73,149,072
Buildings [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property, plant and equipment, gross	32,210,958	31,714,173
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property, plant and equipment, gross	53,272,420	36,919,094
Furniture, Fixtures, Office Equipment and Vehicles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property, plant and equipment, gross	$8,011,586	$8,141,993

PROPERTY_PLANT_AND_EQUIPMENT_N

PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Depreciation	$1,847,248	$1,444,859	$5,136,783	$4,550,598

DEPOSITS_RELATED_TO_LAND_USE_R1

DEPOSITS RELATED TO LAND USE RIGHTS (Narrative) (Details)	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2012	Dec. 31, 2012
	USD ($)	CNY	USD ($)	CNY
Deposits related to land use rights	'	'	$13,552,500	83,400,000
Refunded deposits related to land use rights	$3,737,500	23,000,000	'	'

RESTRICTED_CASH_AND_DEPOSIT_Na

RESTRICTED CASH AND DEPOSIT (Narrative) (Details)

0 Months Ended

Aug. 07, 2013

Apr. 30, 2014

Apr. 30, 2014

Feb. 25, 2014

Feb. 25, 2014

Apr. 30, 2014

Apr. 30, 2014

Feb. 25, 2014

Feb. 25, 2014

Aug. 07, 2013

Aug. 07, 2013

Aug. 31, 2014

Aug. 31, 2014

Feb. 25, 2014

Feb. 25, 2014

Aug. 08, 2013

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank New York Branch [Member]

China Merchants Bank New York Branch [Member]

China Merchants Bank New York Branch [Member]

USD ($)

CNY

24 Month Loan [Member]

24 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

6 Month Loan [Member]

6 Month Loan [Member]

24 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

USD ($)

USD ($)

Restricted Cash and Investments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted Time Deposits

'

'

'

$40,056,250

246,500,000

$30,387,500

187,000,000

$31,622,500

194,600,000

$30,225,000

186,000,000

$31,898,750

196,300,000

'

'

'

Deposit liabilities, collateral issued, financial instruments

'

'

'

40,000,000

'

'

'

30,000,000

'

30,000,000

'

31,525,000

194,000,000

40,000,000

30,000,000

30,000,000

Time Deposits Additional Amount

'

$162,500

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturities of time deposits, description

'August 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

SCHEDULE_OF_SHORTTERM_BANK_LOA

SCHEDULE OF SHORT-TERM BANK LOANS (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Short-term Debt [Line Items]	'	'
Short-term Debt	$75,700,000	$9,822,000
Long-Term Bank Loans Current [Member]	'	'
Short-term Debt [Line Items]	'	'
Maturity date	25-Aug-15	'
Unsecured debt, current	26,300,000	0
Unsecured Loan 1 [Member]	'	'
Short-term Debt [Line Items]	'	'
Maturity date	12-May-14	'
Annual interest rate	6.00%	'
Unsecured debt, current	0	4,911,000
Unsecured Loan 2 [Member]	'	'
Short-term Debt [Line Items]	'	'
Maturity date	22-Dec-14	'
Annual interest rate	6.00%	'
Unsecured debt, current	4,875,000	4,911,000
Unsecured Loan 3 [Member]	'	'
Short-term Debt [Line Items]	'	'
Maturity date	9-Oct-14	'
Annual interest rate	5.60%	'
Unsecured debt, current	13,000,000	0
Secured Loan [Member]	'	'
Short-term Debt [Line Items]	'	'
Maturity date	12-Feb-15	'
Annual interest rate	5.04%	'
Secured debt, current	$31,525,000	$0

SCHEDULE_OF_LONGTERM_BANK_LOAN

SCHEDULE OF LONG-TERM BANK LOANS (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Long-term bank loans	$66,300,000	$30,000,000
Less: current portion of long-term bank loans	26,300,000	0
Total non-current bank loans	$40,000,000	$30,000,000

BANK_LOANS_Narrative_Details

BANK LOANS (Narrative) (Details)

3 Months Ended

9 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Feb. 25, 2014

Feb. 25, 2014

Apr. 30, 2014

Apr. 30, 2014

Feb. 25, 2014

Feb. 25, 2014

Aug. 07, 2013

Aug. 07, 2013

Aug. 31, 2014

Aug. 31, 2014

Feb. 25, 2014

Feb. 25, 2014

Aug. 08, 2013

Jul. 31, 2014

USD ($)

USD ($)

USD ($)

USD ($)

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank New York Branch [Member]

China Merchants Bank New York Branch [Member]

China Merchants Bank New York Branch [Member]

China Merchants Bank New York Branch [Member]

24 Month Loan [Member]

24 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

6 Month Loan [Member]

6 Month Loan [Member]

24 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

18 Month Loan [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

USD ($)

USD ($)

USD ($)

Interest expense on short-term bank loans

$394,338

$79,195

$600,295

$273,095

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan lent period

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

'6 months

'24 months

'18 months

'18 months

'18 months

Line of credit facility, commitment fee percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.20%

1.20%

0.70%

'

Restricted Time Deposits

'

'

'

'

40,056,250

246,500,000

30,387,500

187,000,000

31,622,500

194,600,000

30,225,000

186,000,000

31,898,750

196,300,000

'

'

'

'

Deposit Liabilities, Collateral Issued, Financial Instruments

'

'

'

'

40,000,000

'

'

'

30,000,000

'

30,000,000

'

31,525,000

194,000,000

40,000,000

30,000,000

30,000,000

'

Line of Credit Facility, Interest Rate Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3-month LIBOR plus 1.3% per annum

'3-month LIBOR plus 1.3% per annum

'3-month LIBOR plus 1.6% per annum

'

Repayments of Lines of Credit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,700,000

INCOME_TAX_Narrative_Details

INCOME TAX (Narrative) (Details)	3 Months Ended		9 Months Ended		1 Months Ended	36 Months Ended	1 Months Ended	120 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Oct. 31, 2011	Dec. 31, 2013	Jul. 27, 2011	Dec. 31, 2020
					Shandong Taibang [Member]	Shandong Taibang [Member]	Guizhou Taibang [Member]	Guizhou Taibang [Member]
								Scenario, Forecast [Member]
Effective income tax rate	20.00%	20.00%	18.00%	17.00%	'	'	'	'
Preferential tax rate	'	'	'	'	15.00%	15.00%	15.00%	15.00%

SCHEDULE_OF_STOCK_OPTIONS_ACTI

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) (Stock Option [Member], USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Stock Option [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of Options, Outstanding at beginning	1,882,376	'
Number of Options, Granted	0	'
Number of Options, Exercised	-269,947	'
Number of Options, Forfeited and expired	-32,920	'
Number of Options, Outstanding	1,579,509	1,882,376
Number of Options, Vested and expected to vest	1,579,509	'
Number of Options, Exercisable	1,262,009	'
Weighted Average Exercise Price, Outstanding at beginning	$9.98	'
Weighted Average Exercise Price, Granted	$0	'
Weighted Average Exercise Price, Exercised	$8.37	'
Weighted Average Exercise Price, Forfeited and expired	$11.44	'
Weighted Average Exercise Price, Outstanding	$10.23	$9.98
Weighted Average Exercise Price, Vested and expected to vest	$10.23	'
Weighted Average Exercise Price, Exercisable	$10.36	'
Weighted Average Remaining Contractual Term in Years, Outstanding	'6 years 8 months 1 day	'7 years 2 months 12 days
Weighted Average Remaining Contractual Term in Years, Vested and expected to vest	'6 years 8 months 1 day	'
Weighted Average Remaining Contractual Term in Years, Exercisable	'6 years 4 months 28 days	'
Aggregate Intrinsic Value, Outstanding at beginning	$35,518,897	'
Aggregate Intrinsic Value, Exercised	9,409,238	'
Aggregate Intrinsic Value, Outstanding	69,077,427	35,518,897
Aggregate Intrinsic Value Vested and expected to vest	69,077,427	'
Aggregate Intrinsic Value, Exercisable	$55,026,002	'

SCHEDULE_OF_NONVESTED_SHARES_A

SCHEDULE OF NONVESTED SHARES ACTIVITY (Details) (Non Vested Shares [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Non Vested Shares [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of nonvested shares, Outstanding	362,750
Number of nonvested shares, Granted	294,000
Number of nonvested shares, Vested	-104,625
Number of nonvested shares, Forfeited	-2,500
Number of nonvested shares, Outstanding	549,625
Grant date weighted average fair value, Outstanding	$20.91
Grant date weighted average fair value, Granted	$51.74
Grant date weighted average fair value, Vested	$20.47
Grant date weighted average fair value, Forfeited	$9.85
Grant date weighted average fair value, Outstanding	$37.53

OPTIONS_AND_NONVESTED_SHARES_N

OPTIONS AND NONVESTED SHARES (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Warrants and Options Disclosure [Line Items]	'	'	'	'
Stock compensation expense related to options	$394,769	$651,047	$1,249,663	$3,346,046
Stock compensation expense with respect to non-vested stock option	2,313,967	'	2,313,967	'
Stock compensation expense to be recognized with respect to non-vested stock option	'	'	'1 year 7 months 24 days	'
Stock compensation expense related to nonvested shares	974,601	377,808	2,081,636	730,771
Stock compensation expense to be recognized with respect to non-vested shares	$19,830,214	'	$19,830,214	'
Stock compensation expense with respect to non-vested shares weighted average vesting period	'	'	'3 years 1 month 10 days	'

SCHEDULE_OF_SALES_BY_PRODUCT_T

SCHEDULE OF SALES BY PRODUCT TYPE (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Product Information [Line Items]	'	'	'	'
Sales	$68,923,830	$53,152,141	$185,264,391	$160,764,396
Human Albumin [Member]	'	'	'	'
Product Information [Line Items]	'	'	'	'
Sales	26,367,969	26,420,902	70,639,862	69,686,924
Human Immunoglobulin For Intravenous Injection [Member]	'	'	'	'
Product Information [Line Items]	'	'	'	'
Sales	28,732,092	17,162,545	75,707,888	63,921,570
Other Immunoglobulin Products [Member]	'	'	'	'
Product Information [Line Items]	'	'	'	'
Sales	4,140,522	5,355,020	17,417,328	15,949,006
Placenta Polypeptide [Member]	'	'	'	'
Product Information [Line Items]	'	'	'	'
Sales	7,810,546	2,762,092	17,545,609	7,984,246
Others [Member]	'	'	'	'
Product Information [Line Items]	'	'	'	'
Sales	$1,872,701	$1,451,582	$3,953,704	$3,222,650

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)

1 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

56 Months Ended

31-May-09

Sep. 30, 2014

Jun. 30, 2007

Jul. 31, 2014

Jul. 31, 2014

Dec. 31, 2013

Mar. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Nov. 30, 2010

Nov. 30, 2010

Jun. 30, 2010

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2011

Dec. 31, 2011

Nov. 30, 2013

31-May-07

31-May-07

USD ($)

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Capital commitment, amount committed

'

$5,050,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

91% controlling interest of Guizhou Taibang's shareholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

91.00%

91.00%

Issuance of an additional 20,000,000 shares of Guizhou Taibang

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

20,000,000

Shares price of additionally issued shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.8

Remaining 9% noncontrolling interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.00%

9.00%

Investors agreed to invest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,475,832

50,960,000

Exchange for 18,200,000 shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,200,000

18,200,000

21.4%, of Guizhou Taibang's equity interests

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21.40%

21.40%

Subscribed for 1,800,000 shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,800,000

1,800,000

Share of the 20,000,000 shares being offered

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

20,000,000

Right to acquire common stock shares

'

'

18,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Denied the rights of first refusal of Jie'an over the 18,200,000 shares

18,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Requested that Guizhou Taibang register its 1.8 million shares of additional capital infusion with the local AIC

'

'

'

'

'

1,800,000

1,800,000

'

'

'

'

1,800,000

1,800,000

1,800,000

'

'

'

'

'

Related interest and penalty from May 2007 to December 2011 amounting to RMB 25,000,000

'

'

'

2,240,542

13,809,197

'

'

'

'

'

'

'

'

'

3,967,500

25,000,000

'

'

'

Return over - paid subscription

'

'

'

'

'

'

'

'

'

'

'

'

'

'

228,528

1,440,000

'

'

'

Interest and penalty, amounting to RMB 10,000,000 (approximately $1,587,000) in aggregate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,587,000

10,000,000

'

'

'

Diluted to 71%

'

'

'

'

'

'

'

'

'

'

'

'

71.00%

71.00%

'

'

'

'

'

Payables to Jie an for the additional funds received

'

'

'

'

'

'

'

'

'

'

'

'

819,000

5,040,000

'

'

'

'

'

Payables to Jie an for over-paid subscription

'

'

'

'

'

'

'

'

'

'

'

'

234,000

1,440,000

'

'

'

'

'

Payable to Jie an for the accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

525,776

3,235,544

'

'

'

'

'

Company returned proceeds

'

'

'

'

'

'

'

'

'

1,699,040

11,200,000

'

'

'

'

'

'

'

'

Request for distribution of dividends of $2,990,943 (or RMB 18,349,345)

'

'

'

'

'

'

'

2,981,769

18,349,345

'

'

'

'

'

'

'

'

'

'

Request for interest in amount of $464,061 (or RMB 2,847,000)

'

'

'

'

'

'

'

462,638

2,847,000

'

'

'

'

'

'

'

'

'

'

Accrued Interest

'

'

'

'

'

'

'

'

'

'

'

'

3,088,103

19,003,712

'

'

'

'

'

Penalty

'

'

'

'

'

'

'

'

'

'

'

'

$82,810

509,600

'

'

'

'

'

Penalty Imposed By The Agreement

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

1.00%

'

'

'

'

'

Number of shares failed to register

'

'

'

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Capital Shares Reserved for Future Issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

SCHEDULE_OF_MATERIAL_RELATED_P

SCHEDULE OF MATERIAL RELATED PARTY TRANSACTIONS (Details) (USD $)	3 Months Ended				9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013
Related Party Transactions [Line Items]	'		'		'		'
Commission expenses with related parties	$0	[1]	$815,410	[1]	$2,249,716	[1]	$2,367,722	[1]
[1]	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Pharmaceutical Co., Ltd. (bGuizhou Eakanb), one of the former Guizhou Taibangbs noncontrolling interest shareholders (see note 18), pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. The agency contract expired on May 31, 2014 and Guizhou Eakan no longer provided the promotion services thereafter. At September 30, 2014 and December 31, 2013, Guizhou Taibang accrued commission payable of $8,125 and $351,955 for service rendered by Guizhou Eakan, respectively. For the three months ended September 30, 2014 and 2013, commission expense for service rendered by Guizhou Eakan was nil and $815,410, respectively. For the nine months ended September 30, 2014 and 2013, commission expense for service rendered by Guizhou Eakan was $2,249,716 and $2,367,722, respectively.

SCHEDULE_OF_RELATED_PARTY_TRAN

SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013
Related Party Transaction [Line Items]	'		'
Total other payable - related parties	$3,952,901		$7,206,970
Commission [Member]	'		'
Related Party Transaction [Line Items]	'		'
Total other payable - related parties	8,125	[1]	351,955	[1]
Loan [Member]	'		'
Related Party Transaction [Line Items]	'		'
Total other payable - related parties	2,366,000	[2]	2,383,472	[2]
Contribution One [Member]	'		'
Related Party Transaction [Line Items]	'		'
Total other payable - related parties	0	[3]	2,929,903	[3]
Contribution Two [Member]	'		'
Related Party Transaction [Line Items]	'		'
Total other payable - related parties	$1,578,776	[4]	$1,541,640	[4]
[1]	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Pharmaceutical Co., Ltd. (bGuizhou Eakanb), one of the former Guizhou Taibangbs noncontrolling interest shareholders (see note 18), pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. The agency contract expired on May 31, 2014 and Guizhou Eakan no longer provided the promotion services thereafter. At September 30, 2014 and December 31, 2013, Guizhou Taibang accrued commission payable of $8,125 and $351,955 for service rendered by Guizhou Eakan, respectively. For the three months ended September 30, 2014 and 2013, commission expense for service rendered by Guizhou Eakan was nil and $815,410, respectively. For the nine months ended September 30, 2014 and 2013, commission expense for service rendered by Guizhou Eakan was $2,249,716 and $2,367,722, respectively.
[2]	Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,366,000 and $2,383,472 at September 30, 2014 and December 31, 2013, respectively. Guizhou Eakan Investing Corp. is an affiliate of Guizhou Eakan. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand.
[3]	In December 2013, Guizhou Taibang received a contribution of RMB17,898,000 (approximately $2,908,425) from Guizhou Eakan, pending for the registration with the local AIC. In August 2014, the Company acquired the equity interest owned by Guizhou Eakan in Guizhou Taibang and made the registration accordingly.
[4]	Guizhou Taibang has payables to Jieban, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $1,578,776 and $1,541,640 at September 30, 2014 and December 31, 2013, respectively. In 2007, Guizhou Taibang received additional contributions from Jieban of $962,853 (or RMB6,480,000) to maintain Jiebanbs equity interest in Guizhou Taibang at 9%. However, due to a legal dispute among shareholders over raising additional capital as discussed in the legal proceeding section (see Note 13), the contribution is subject to be returned to Jieban. During the second quarter of 2010, Jieban requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC, pursuant to the Equity Purchase Agreement, and such registration was approved by the majority shareholders of Guizhou Taibang in a shareholdersb meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholdersb approval of Jiebanbs request until the completion of the ongoing litigations. If the Company decided to ratify the approval, Dalinbs ownership in Guizhou Taibang will be diluted to 71% and Jieban will be entitled to receive its pro rata share of Guizhou Taibangbs profits since the date on which Jiebanbs contribution became effective. As this case is closely tied to the outcome of the strategic investorsb dispute stated above, the Company has recorded, in its balance sheet, payables to Jieban in the amounts of RMB5,040,000 (approximately $819,000) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $234,000) for the over-paid subscription and RMB3,235,544 (approximately $525,776) for the accrued interest and penalty at September 30, 2014.

RELATED_PARTY_TRANSACTIONS_Nar

RELATED PARTY TRANSACTIONS (Narrative) (Details)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2010

Dec. 31, 2007

Dec. 31, 2007

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Share data in Millions, unless otherwise specified

USD ($)

USD ($)

Jiean [Member]

Jiean [Member]

Guizhou Eakan Investing Corp [Member]

Guizhou Eakan Investing Corp [Member]

Guizhou Taibang [Member]

Guizhou Taibang [Member]

Guizhou Taibang [Member]

Guizhou Taibang [Member]

Guizhou Taibang [Member]

Guizhou Taibang [Member]

Commission [Member]

Commission [Member]

Commission [Member]

Commission [Member]

USD ($)

CNY

USD ($)

USD ($)

USD ($)

CNY

USD ($)

CNY

Guizhou Eakan [Member]

Guizhou Eakan [Member]

Guizhou Eakan [Member]

Guizhou Eakan [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commission Payable

$8,125

$351,955

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commission expense for service rendered

'

'

'

'

'

'

'

'

'

'

'

'

0

815,410

2,249,716

2,367,722

Payables to Guizhou Eakan Investing Corp.

'

'

'

'

2,366,000

2,383,472

'

'

'

'

'

'

'

'

'

'

Guizhou Taibang received additional contributions

'

'

'

'

'

'

'

2,908,425

17,898,000

'

962,853

6,480,000

'

'

'

'

Payables to Jie'an Noncontrolling Interest

1,578,776

1,541,640

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maintain Jie'an equity interest in Guizhou Taibang at 9%

'

'

'

'

'

'

'

'

'

'

9.00%

9.00%

'

'

'

'

Jie'an requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC

'

'

'

'

'

'

'

'

'

1.8

'

'

'

'

'

'

Ownership in Guizhou Taibang will be diluted to 71%

'

'

'

'

'

'

71.00%

'

'

'

'

'

'

'

'

'

Jie'an's additional fund

'

'

819,000

5,040,000

'

'

'

'

'

'

'

'

'

'

'

'

Payables to Jie'an for over-paid subscription

'

'

234,000

1,440,000

'

'

'

'

'

'

'

'

'

'

'

'

Accrued interest and penalty for Jie'an's additional fund

'

'

$525,776

3,235,544

'

'

'

'

'

'

'

'

'

'

'

'

SCHEDULE_OF_NET_INCOME_PER_SHA

SCHEDULE OF NET INCOME PER SHARE RECONCILIATION (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net income attributable to China Biologic Products, Inc.	$20,060,066	$14,696,023	$58,058,692	$45,773,809
Earnings allocated to participating nonvested shares	-342,190	-143,220	-895,840	-303,490
Net income used in basic/diluted net income per common stock	$19,717,876	$14,552,803	$57,162,852	$45,470,319

SCHEDULE_OF_NET_INCOME_PER_SHA1

SCHEDULE OF NET INCOME PER SHARE - BASIC AND DILUTED (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Weighted average shares used in computing basic net income per common stock	24,548,042	26,288,154	24,325,752	26,649,563
Diluted effect of stock option	1,239,064	1,160,927	1,242,763	1,130,442
Weighted average shares used in computing diluted net income per common stock	25,787,106	27,449,081	25,568,515	27,780,005
Net income per common stock - basic	$0.80	$0.55	$2.35	$1.71
Net income per common stock - diluted	$0.76	$0.53	$2.24	$1.64

NET_INCOME_PER_SHARE_Narrative

NET INCOME PER SHARE (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Options excluded from the calculation of diluted net income per share of common stock	0	0	0	0

SHARE_REPURCHASE_Narrative_Det

SHARE REPURCHASE (Narrative) (Details) (USD $)	1 Months Ended
	Feb. 28, 2014
Accelerated Share Repurchases [Line Items]	'
Treasury Stock, Shares, Acquired	2,500,000
Treasury Stock Value Acquired	$70,000,000

FOLLOWON_OFFERING_OF_COMMON_ST1

FOLLOW-ON OFFERING OF COMMON STOCK (Narrative) (Details) (USD $)	0 Months Ended	1 Months Ended
In Millions, except Share data, unless otherwise specified	Jul. 02, 2014	Jul. 31, 2014
Subsequent Event [Line Items]	'	'
Shares Of Common Stock That Is Offered To Sell	1,782,500	'
Shares Issued, Price Per Share	$38	'
Stock Issued During Period, Shares, Treasury Stock Reissued	'	920,000
Number Of Shares Sold By Stockholders	'	862,500
Purchase Option Of Additional Number Of Shares Of Common Stock From Company	'	120,000
Purchase Option Of Additional Number Of Shares Of Common Stock From Selling Stockholder	'	112,500
Proceeds from Issuance or Sale of Equity	'	$33.20

ACQUISITION_OF_ADDITIONAL_EQUI1

ACQUISITION OF ADDITIONAL EQUITY INTEREST IN GUIZHOU TAIBANG (Narrative) (Details) (Guizhou Eakan Pharmaceutical Co., Ltd [Member])	0 Months Ended
In Millions, unless otherwise specified	Aug. 25, 2014	Aug. 25, 2014
	USD ($)	CNY
Business Acquisition [Line Items]	'	'
Acquisition of Equity Method Investment Ownership Additional Percentage	19.84%	19.84%
Business Combination, Consideration Transferred	$86.90	535
Equity Method Investment, Ownership Percentage	76.23%	76.23%